Vascular endothelial growth factor, a specific regulator of angiogenesis

Current Opinion in Nephrology and Hypertension

Volumn 5, Issue 1, 1996, Pages 35-44

  Ferrara, Napoleone ^a   Bunting, Stuart ^a  

^a GENENTECH INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENIC FACTOR; ENDOTHELIAL CELL GROWTH FACTOR; ENDOTHELIAL CELL GROWTH FACTOR RECEPTOR; UNCLASSIFIED DRUG;

ANGIOGENESIS; HUMAN; PRIORITY JOURNAL; REVIEW; VASCULAR ENDOTHELIUM;

EID: 0029981701     PISSN: 10624821     EISSN: None     Source Type: Journal    
DOI: 10.1097/00041552-199601000-00008     Document Type: Review

References (124)

1. Klagsbrun M, D'Amore PA: Regulation of angiogenesis. Annu Rev Physiol 1991, 53:217-239.
2. Folkman J: What is the evidence that tumors are angiogenesis-dependent? J Natl Cancer Inst 1991, 82:4-6.
3. Folkman J, Shing Y: Angiogenesis. J Biol Chem 1992, 267:10931-10934.
4. Garner A: Vascular diseases. In Pathobiology of ocular disease. A dynamic approach. 2nd edn. Edited by Garner A, Klintworth GK. New York: Marcel Dekker 1994: 1625-1710.
5. Weidner N, Semple P, Welch W, Folkman J: Tumor angiogenesis and metastasis. Correlation in invasive breast carcinoma. N Engl J Med 1991, 324:1-6.
6. Weidner N, Folkman J, Pozza F, Bevilacqua P, Allred EN, Moore DH, Meli S, Gasparini G: Tumor angiogenesis: a new significant and Independent prognostic indicator in early-stage breast carcinoma. J Natl Cancer Inst 1992, 84:1875-1888.
7. Wakui S, Furusato M, Sasaki H, Akiyama A, Kinoshito I, Asano K, Tokuda T, Aizawa S, Ushigome S: Tumor angiogenesis in prostatic carcinoma with and without bone metastasis: a morphometric study. J Pathol 1992, 168:257-262.
8. Bigler SA, Deering RE, Brawer MK: Comparison of microscopic vascularity in benign and malignant prostatic tissue. Hum Pathol 1993, 24:220-226.
9. Chodak GW, Haudenschild C, Gittes RF, Folkman J: Angiogenic activity as a marker of neoplastic and preneoplastic lesions of the human bladder. Ann Surg 1980, 192:762-771.
10. Macchiarini P, Fontanini G, Hardin MJ, Squartini F, Angeletti CA: Relation of neovascularization to metastasis of non-small cell lung carcinoma. Lancet 1992, 340:145-146.
11. Sillman F, Boyce J, Fruchter R: The significance of atypical vessels and neovascularization in cervical neoplasias. Am J Obstet Gynecol 1981, 139:154-157.
12. Ferrara N, Henzel WJ: Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothellal cells. Biochem Biophys Res Commun 1989, 161:851-859.
13. Ferrara N, Houck K, Jakeman L, Leung DW: Molecular and biological properties of the vascular endothelial growth factor family of proteins. Endocr Rev 1992, 13:18-32.
14. Ploüet J, Schilling J, Gospodarowicz D: Isolation and characterization of a newly identified endothelial cell mitogen produced by AtT20 cells. EMBO J 1989, 8:3801-3807.
15. Conn G, Bayne M, Soderman L, Kwok PW, Sullivan KA, Palisi TM, Hope DA, Thomas KA: Amino acid and cDNA sequence of a vascular endothelial cell mitogen homologous to platelet-derived growth factor. Proc Natl Acad Sci U S A 1990, 87:2628-2632.
16. Breier G, Albrecht U, Sterrer S, Risau W: Expression of vascular endothelial growth factor during embryonic angiogenesis and endothelial cell differentiation. Development 1992, 114:521-532.
17. Phillips HS, Hains J, Leung DW, Ferrara N: Vascular endothelial growth factor is expressed in rat corpus luteum. Endocrinology 1990, 127:965-968.
18. Shweiki D, Itin A, Neufeld G, Gitay-Goren H, Keshet E: Patterns of expression of vascular endothelial growth factor (VEGF) and VEGF receptors in mice suggest a role in hormonally regulated angiogenesis. J Clin Invest 1993, 91:2235-2243.
19. Banai S, Jaktlish MT, Shou M, Lazarous DF, Scheinowitz M, Biro S, Epstein S, Unger E: Angiogenic-induced enhancement of collateral blood flow to ischemic myocardium by vascular endothelial growth factor in dogs. Circulation 1994, 89:2183-2189. This study presents evidence for the ability of VEGF to promote collateral flow in a canine model of occlusion of the circumflex artery.
20. Harada K, Friedman M, Lopez J, Prasad PV, Hibberd M, Pearlman JD, Sellke FW, Simons M: Vascular endothelial growth factor improves coronary flow and myocardial function in chronically ischemic porcine hearts. Nature Med (in press). This paper demonstrates that minute concentrations of VEGF extraluminally applied are able to profoundly improve coronary blood flow and myocardial function in a porcine model.
21. Takeshita S, Zhung L, Brogi E, Kearney M, Pu L-Q, Bunting S, Ferrara N, Symes JF, Isner JM: Therapeutic angiogenesis: a single intra-arterial bolus of vascular endothelial growth factor augments collateral vessel formation in a rabbit ischemic hindlimb model. J Clin Invest 1994, 93:662-670. This article provides the first evidence that VEGF administration promotes collateral vessel growth in an animal model of limb ischemia.
22. Takeshita S, Zheng LP, Cheng D, Riessen R, Weir L, Symes JF, Ferrara N, Isner JM: Therapeutic angiogenesis following arterial gene transfer of vascular endothelial in a rabbit model of hindlimb ischemia. Proc Natl Acad Sci U S A (in press).
23. Kim KJ, Li B, Winer J, Armanini M, Gillett N, Phillips HS, Ferrara N: Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 1993, 362:841-844.
24. Aiello LP, Avery R, Arrigg R, Keyt B, Jampel H, Shah S, Pasquale L, Thieme H, Iwamoto M, Park JE, et al.: Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 1994, 331:1480-1487. This paper demonstrates a temporal correlation between VEGF levels in the eye fluids and intra-ocular neovascularization. In a large series (164 patients), VEGF levels were found to be elevated in the aqueous and vitreous humor of patients with active proliferative retinopathy secondary to diabetes, prematurity, or occlusion of the central retinal vein. However, VEGF was not detectable prior to active proliferative retinopathy or in proliferative retinopathy in a quiescent phase.
25. Ferrara N: Vascular endothelial growth factor - the trigger for neovascularization in the eye [Editorial]. Lab Invest 1995, 72:615-618.
26. Leung DW, Cachianes G, Kuang W-J, Goeddel DV, Ferrara N: Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 1989, 246:1306-1309.
27. 165) stimulates direct anglogenesls in the rabbit cornea. In Vivo 1995, 8:961-965.
28. Connolly DT, Heuvelman DM, Nelson R, Olander JV, Eppley BL, Delfino JJ, Siegel NR, Leimgruber RM, Feder J: Tumor vascular permeability factor stimulates endothelial cell growth and angiogenesis. J Clin Invest 1989, 84:1470-1478.
29. Pepper MS, Ferrara N, Orci L, Montesano R: Potent synergism between vascular endothelial growth factor and basic fibroblast growth factor in the induction of angiogenesis in vitro. Biochem Biophys Res Commun 1992, 189:824-831.
30. Nicosia RF, Nicosia SV, Smith M: Vascular endothelial growth factor, platelet-derived growth factor and insulin-like growth factor-1 promote rat aortic angiogenesis in vitro. Am J Pathol 1995, 145:1023-1029.
31. Pepper MS, Ferrara N, Orci L, Montesano R: Vascular endothelial growth factor (VEGF) induces plasminogen activators and plasminogen activator inhibitor type 1 in microvascular endothelial cells. Biochem Biophys Res Commun 1991, 181:902-908.
32. Unemori E, Ferrara N, Bauer EA, Amento EP: Vascular endothelial growth factor induces interstitial collagenase expression in human endothelial cells. J Cell Physiol 1992, 153:557-562.
33. Mandriota S, Montesano R, Orci L, Seghezzi G, Vassalli J-D, Ferrara N, Mignatti P, Pepper MS: Vascular endothelial growth factor increases urokinase receptor expression in vascular endothelial cells. J Biol Chem 1995, 270:9709-9716.
34. Connolly DT, Olander JV, Heuvelman D, Nelson R, Monsell R, Siegel N, Haymore BL, Leingruber R, Feder J: Human vascular permeability factor. Isolation from U937 cells. J Biol Chem 1989, 254:20017-20024.
35. Keck PJ, Hauser SD, Krivi G, Sanzo K, Warren T, Feder J, Connolly DT: Vascular permeability factor, an endothelial cell mitogen related to platelet derived growth factor. Science 1989, 246:1309-1312.
36. Senger Dr, Galli SJ, Dvorak AM, Perruzzi CA, Harvey VS, Dvorak HF: Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 1983, 219:983-985.
37. Dvorak HF: Tumors: wound that do not heal. Similarity between tumor stroma generation and wound healing. N Engl J Med 1986, 315:1650-1658.
38. Dvorak HF, Harvey VS, Estrella P, Brown LF, McDonagh J, Dvorak AM: Fibrin containing gels induce anglogenesis: implications for tumor stroma generation and wound healing. Lab Invest 1987, 57:673-686.
39. Pekala P, Marlow M, Heuvelman D, Connolly D: Regulation of hexose transport in aortic endothelial cells by vascular permeability factor and tumor necrosis factor-alpha, but not by insulin. J Biol Chem 1990, 265:18051-18054.
40. Clauss M, Gerlach M, Gerlach H, Brett F, Wang F, Familletti PC, Pan Y-C, Olander JV, Connolly DT, Stern D: Vascular permeability factor: a tumor-derived polypeptide that induces endothelial cell and monocyte procoagulant activity, and promotes monocyte migration. J Exp Med 1990, 172:1535-1545.
41. Ku DD, Zaleski JK, Liu S, Brock T: Vascular endothelial growth factor induces EDRF-dependent relaxation of coronary arteries. Am J Physiol 1993, 265:H586-H592.
42. Park JE, Chen H, Winer J, Houck K, Ferrara N: Placenta growth factor. Potentiation of vascular endothelial growth factor bloactivity, in vitro and in vivo, and high affinity binding to Flt-1 but not to Flk-1/KDR. J Biol Chem 1994, 269:25646-25654. This article shows that RGF, a VEGF-related molecule devoid of significant mitogenic activity, binds to Flt-1 but not to KDR, a receptor which now is thought to be critical for VEGF-induced mitogenesis and angiogenesis.
43. Maglione D, Guerriero V, Viglietto G, Delli-Bovi P, Persico MG: Isolation of a human placenta cDNA coding for a protein related to the vascular permeability factor. Proc Natl Acad Sci U S A 1991, 88:9267-9271.
44. Hauser S and Weich HA: A heparin-binding form of placenta growth factor (PIGF-2) is expressed in human umbilical vein endothelial cells and in placenta. Growth Factors 1993, 9:259-268.
45. Tisher E, Mitchell R, Hartmann T, Silva M, Gospodarowicz D, Fiddes J, Abraham J: The human gene for vascular endothelial growth factor. J Biol Chem 1991, 266:11947-11954.
46. Houck KA, Ferrara N, Winer J, Cachianes G, Li B, Leung DW: The vascular endothelial growth factor family: identification of a fourth molecular species and characterization of alternative splicing of RNA. Mol Endocrinol 1991, 5:1806-1814.
47. Houck KA, Leung DW, Rowland AM, Winer J, Ferrara N: Dual regulation of vascular endothelial growth factor bloavailability by genetic and proteolytic mechanisms. J Biol Chem 1992, 267:26031-26037.
48. Park JE, Keller G-A, Ferrara N: The vascular endothelial growth factor (VEGF) isoforms: differential deposition into the subepithelial extracellular matrix and bioactivity of ECM-bound VEGF. Mol Biol Cell 1993, 4:1317-1326.
49. Mignatti P, Tsuboi R, Robbins E, Rifkin DB: In vitro angiogenesis on the human amniotic membrane: requirement for basic fibroblast growth factor-induced proteinase. J Cell Biol 1989, 108:671-682.
50. DiSalvo J, Bayne ML, Conn G, Kwok PW, Trivedi PG, Soderman DD, Palisi TM, Sullivan KA, Thomas KA: Purification and characterization of a naturally occurring vascular endothelial growth factor-placenta growth factor heterodimer. J Biol Chem 1995, 270, 7717-7723. This study presents evidence for the existence of naturally occurring heterodimers between VEGF and PIGF. Because the heterodimer was significantly less potent than the VEGF heterodimer, this may represent a means to modulate the bioactivity of VEGF.
51. Minchenko A, Bauer T, Salceda S, Caro J: Hypoxic stimulation of vascular endothelial growth factor expression in vivo and in vitro. Lab Invest 1994, 71:374-379.
52. Shweiki D, Itin A, Soffer D, Keshet E: Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated anglogenesis. Nature 1992, 359:843-845.
53. Shima DT, Adamis AP, Ferrara N, Yeo K-T, Yeo T-K, Allende, Folkman J, D'Amore PA: Hypoxic induction of vascular endothelial cell growth factors in the retina: identification and characterization of vascular endothelial growth factor (VEGF) as the sole mitogen. Mol Med 1995, 2:64-71.
54. Banai S, Shweiki D, Pinson A, Chandra M, Lazarovici G, Keshet E: Upregulation of vascular endothelial growth factor expression induced by myocardial ischemia: implications for coronary angiogenesis. Cardiovasc Res 1994, 28:1176-1179.
55. Goldberg MA and Schneider TJ: Similarities between the oxygen-sensing mechanisms regulating the expression of vascular endothelial growth factor and erythropoietin. J Biol Chem 1994, 269:4355-4361. This article provides the first evidence for similarities between the oxygen-sensing mechanism involved in the regulation of the vegf and Epo genes.
56. Levy AP, Levy NS, Wegner S, Goldberg MA: Transcriptional regulation of the rat vascular endothelial growth factor gene by hypoxia. J Biol Chem 1995, 270:13333-13340.
57. Madan A, Curtin PT: A 24-base pair sequence 3′ to the human erythropoietin contains a hypoxia-responsive transcriptional enhancer. Proc Natl Acad Sci U S A 1993, 90:3928-3932.
58. 2 tension. Proc Natl Acad Sci U S A 1995, 92:5510-5514.
59. Mukhopadhyay D, Tsilokas L, Zhou X-M, Foster D, Brugge JS, Sukhatme VP: Hypoxic induction of human vascular endothelial growth factor expression through c-Src activation. Nature 1995, 375:577-581.
60. Frank S, Hubner G, Breier G, Longaker MT, Greenhalgh DG, Werner S: Regulation of VEGF expression in cultured keratinocytes. Implications for normal and impaired wound healing. J Biol Chem 1995, 270:12607-12613. This paper describes the upregulation of VEGF mRNA in the skin. Interestingly, such upregulation is impaired in diabetic mice.
61. Pertovaara L, Kaipainen A, Mustonen T, Orpana A, Ferrara N, Saksela O, Alitalo K: Vascular endothelial growth factor is induced in response to transforming growth factor-β in fibroblastic and epithelial cells. J Biol Chem 1994, 69:6271-6274.
62. Li J, Perrella MA, Tsai JC, Yet SF, Hsieh CM, Yoshizumi M, Patterson C, Endego WO, Zhou F, Lee M: Induction of vascular endothelial growth factor gene expression by interteukin-1 beta in rat aortic smooth muscle cells. J Biol Chem 1995, 270:308-312.
63. Claffey KP, Wilkinson WO, Spiegelman BM: Vascular endothelial growth factor. Regulation by cell differentiation and activated second messenger pathways. J Biol Chem 1992, 267:16317-16322.
64. Kieser A, Weich H, Brandner G, Marme D, Kolch W: Mutant p53 potentiates protein kinase C induction of vascular endothelial growth factor expression. Oncogene 1994, 9:963-969.
65. Vaisman N, Gospodarowicz D, Neufeld G: Characterization of the receptors for vascular endothelial growth factor. J Biol Chem 1990, 265:19461-19469.
66. Ploüet J, Moukadiri HJ: Characterization of the receptors to vasculotropin on bovine adrenal cortex-derived capillary endothelial cell. J Biol Chem 1990, 265:22071-22075.
67. Thieme H, Aiello LP, Ferrara N, King GL: Comparative analysis of VEGF receptors on retinal and aortic endothelial cells. Diabetes 1995, 44:98-103.
68. Jakeman LB, Winer J, Bennett GL, Altar CA, Ferrara N: Binding sites for vascular endothelial growth factor are localized on endothelial cells in adult rat tissues. J Clin Invest 1992, 89:244-253.
69. Jakeman LB, Armanini M, Phillips HS, Ferrara N: Developmental expression of binding sites and mRNA for vascular endothelial growth factor suggests a role for this protein in vasculogenesis and angiogenesis. Endocrinology 1993, 133:848-859.
70. deVries C, Escobedo JA, Ueno H, Houck KA, Ferrara N, Williams LT: The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. Science 1992, 255:989-991.
71. Terman BI, Vermazen MD, Carrion ME, Dimitrov D, Armellino DC, Gospodarowicz D, Bohlen P: Identification of the KDR tyrosine kinase as a receptor for vascular endothelial growth factor. Biochem Biophys Res Commun 1992, 34:1578-15786.
72. Quinn T, Peters KG, deVries C, Ferrara N, Williams LT: Fetal liver kinase 1 is a receptor for vascular endothellal growth factor and is selectively expressed in vascular endothellum. Proc Natl Acad Sci U S A 1993, 90:7533-7537.
73. Millauer B, Wizigmann-Voos S, Schnurch H, Martinez R, Moller NP, Risau W, Ullrich A: High affinity binding and developmental expression suggest Flk-1 as a major regulator of vasculogenesis and angiogenesis. Cell 1993, 72:835-846.
74. Shibuya M, Yamaguchi S, Yamane A, Ikada T, tojo T, Matsushime H, Sato M: Nucleotide sequence and expression of a novel human receptor-type tyrosine kinase (flt) closely related to the fms family. Oncogene 1990, 8:519-527.
75. Terman BI, Carrion ME, Kovacs E, Rasmussen BA, Eddy RL, Shows TB: Identification of a new endothelial cell growth factor receptor tyrosine kinase. Oncogene 1991, 6:519-524.
76. Matthews W, Jordan CT, Gavin M, Jenkins NA, Copeland NG, Lemischka IR: A receptor tyrosine kinase cDNA isolated from a population of enriched primitive hematopoietic cells and exhibiting close genetic linkage to c-kit. Proc Natl Acad Sci U S A 1991, 88:9026-9030.
77. Kendell RL, Thomas KA: Inhibition of vascular endothelial growth factor by an endogenously encoded soluble receptor. Proc Natl Acad Sci U S A 1993, 90:1005-1009.
78. Peters KG, deVries C, Williams LT: Vascular endothellal growth factor receptor expression during embryogenesis and tissue repair suggests a role in endothelial differentiation and blood vessel growth. Proc Natl Acad Sci U S A, 1993, 90:8915-8919.
79. •] provide evidence for differential signal transducing properties of the VEGF receptors Flt-1 and KDR.
80. •].
81. Fong G-H, Rassant J, Gertenstein M, Breitman M: Role of Flt-1 receptor tyrosine kinase in regulation of assembly of vascular endothellum. Nature 1995, 376:6670. This article and [86••] demonstrate that targeted mutations that inactivate the VEGF receptors disrupt the assembly of the vascular endothelium, impair vasculogenesis and blood island formation, and result in early intrauterine death.
82. ••].
83. Evans HM: On the development of aortae, cardinal, umbilical veins, and other blood vessels of vertebrate embryos from capillaries. Anat Rec 1909, 3:498-516.
84. Shifren JL, Doldi N, Ferrara N, Mesiano S, Jaffe RB: In the human fetus, vascular endothelial growth factor (VEGF) is expressed in epithelial cells and myocytes, but not vascular endothelium: Implications for mode of action. J Clin Endocrinol Metab 1994, 79:316-322.
85. Monacci W, Merrill M, Oldfield E: Expression of vascular permeability factor/vascular endothellal growth factor in normal rat tissues. Am J Physiol 1993, 264, C995-C1002.
86. Brown LF, Berse B, Tognazzi K, Manseau EJ, Van de Water L, Senger DR, Dvorak HF, Rosen S: Vascular permeability factor mRNA and protein expression in human kidney. Kidney Int 1992, 42:1457-1461.
87. Ravindranath N, Little-Ihrig L, Phillips HS, Ferrara N, Zeleznick AJ: Vascular endothellal growth factor mRNA expression in the primate ovary. Endocrinology 1992, 131:254-260.
88. Senger D, Perruzzi CA, Feder J, Dvorak HF: A highly conserved vascular permeability factor secreted by a variety of human and rodent tumor cell lines. Cancer Res 1986, 46:5269-5275.
89. Rosenthal R, Megyesi JF, Henzel WJ, Ferrara N, Folkman J: Conditioned medium from mouse sarcoma 180 cells contains vascular endothelial growth factor. Growth Factors 1990, 4:53-59.
90. Dvorak HF, Brown LF, Detmar M, Dvorak AM: Vascular permeability factor/vascular endothelial growth factor, microvascular permeability and angiogenesis. Am J Pathol 1995, 146:1029-1039.
91. Plate KH, Breier G, Weich HA, Risau W: Vascular endothelial growth is a potential tumour angiogenesis factor in vivo. Nature 1992, 359:845-847.
92. Phillips HS, Armanini M, Stavrou D, Ferrara N, Westphal M: Intense focal expresson of vascular endothelial growth factor mRNA in human intracranial neoplasms: association with regions of necrosis. Int J Oncol 1993, 2:913-919.
93. Berkman RA, Merrill MJ, Reinhold WC, Monacci WT, Saxena A, Clark WC, Robertson JT, Ali IU, Oldfield EH: Expression of the vascular permeability/vascular endothelial growth factor gene in central nervous system neoplasms. J Clin Invest 1993, 91:153-159.
94. Wizigmann-Voss S, Breier G, Risau W, Plate K: Up-regulation of vascular endothelial growth factor and its receptors in von Hippel-Lindau disease-associated and sporadic hemangioblastoma. Cancer Res 1994, 55:1358-1364.
95. Warren RS, Yuan H, Matli MR, Gillett NA, Ferrara N: Regulation by vascular endothelial growth factor of human colon cancer tumorigenesis in a mouse model of experimental liver metastasis. J Clin Invest 1995, 95:1789-1797. This article shows that anti-VEGF monoclonal antibodies dramatically suppress intrahepatic growth of colon cancer cells in a murine model of liver metastasis.
96. Toi M, Hoshima S, Takayanagi T, Tominaga T: Association of vascular endothelial growth factor expression with tumor angiogenesis and with early relapse in primary breast cancer. Jpn J Cancer Res 1994, 85:1045-1049.
97. Ferrara N, Winer J, Burton T, Rowland A, Siegel M, Phillips HS, Terrell T, Keller G-A, Levinson AD: Expression of vascular endothelial growth factor does not promote transformation but confers a growth advantage in vivo to Chinese hamster ovary cells. J Clin Invest 1993, 91:160-170.
98. Kim KJ, Li B, Houck K, Winer J, Ferrara N: The vascular endothelial growth factor proteins: identification of biologically relevant regions by neutralizing monoclonal antibodies. Growth Factors, 1992, 7:53-64.
99. Millauer B, Shawver LK, Plate KH, Risau W, Ullrich A: Glioblastoma growth is inhibited in vivo by a negative dominant Flk-1 mutant Nature 1994, 367:576-579. This study shows that inhibition of VEGF action by a negative dominant Flk-1 receptor suppresses tumor growth in vivo.
100. Patz A: Studies on retinal neovascularization. Invest Ophthalmol Vis Sci 1980, 19:1133-1138.
101. Olk RJ, Lee CM: Diabetic retinopathy: practical management. Pennsylvania, Philadelphia: Lippincott Co.; 1993.
102. Michaelson IC: The mode of development of the vascular system of the retina with some observations on its significance for certain retinal disorders. Trans Ophthalmol Soc UK 1948, 68:137-180.
103. •] present evidence for elevations of VEGF levels in the eyes of patients affected by diabetic retinopathy.
104. •].
105. Pe'er J, Shweiki D, Itin A, Hemo I, Gnessin H, Keshet E: Hypoxia-induced expression of vascular endothelial growth factor (VEGF) by retinal cells is a common factor in neovascularization. Lab Invest 1995, 72:638-645. This study documents the upregulation of VEGF mRNA in the retina of patients with various ischemic retinal disorders. Interestingly, in each of these conditions, VEGF mRNA upregulation occurred only in the retinal layer expected to be ischemic.
106. •] demonstrate a temporal and spatial correlation between VEGF expression and neovascularization in two animal models of ischemia.
107. •].
108. ••] provide a direct demonstration that VEGF is a major mediator of neovascularization associated with ischemic retinal disorders.
109. ••].
110. •] suggest that VEGF is implicated in the neovascularization associated with rheumatoid arthritis.
111. Fava RA, Olsen NJ, Spencer-Green G, Yeo T-K, Yeo K-T, Berse B, Jackman RW, Senger DR, Dvorak HF, Brown LF: Vascular permeability factor/vascular endothelial growth factor (VPF/VEGF): accumulation and expression in human synovial fluids and rheumatoid arthritis. J Exp Med 1994, 180:340-346. See [110•].
112. Fassbender HJ, Simling-Annefeld M: The potential aggressiveness of synovial tissue in rheumatoid arthritis. J Pathol 1983, 139:399-406.
113. Brown LF, Harris TJ, Yeo KT, Stahle-Backdahl M, Jackman RW, Berse B, Tognazzi K, Dvorak HF, Detmar M: Increased expression of vascular permeability factor (vascular endothelial growth factor) in bullous pemphigoid, dermatitits herpetiformis and herythema multiforme. J Invest Dermatol 1995, 104:744-749.
114. Lyttle DJ, Fraser KM, Flemmings SB, Mercer AA, Robinson AJ: Homologs of vascular endothelial growth factor are encoded by the poxvirus orf virus. J Virol 1994, 68:84-92.
115. Thompson RW, D'Amore PA: Recruitment of growth and collateral circulation. In Clinical ischemic syndromes: mechanisms and consequences of tissue injury. Edited by Zelenock GB, D'Alecy LG, Fantone JC III, Shlafer M, Stanley JC. St Louis: CV Mosby; 1990: 117-134.
116. Takeshita S, Pu L-Q, Stein LA, Sniderman AD, Bunting S, Ferrara N, Isner JM, Symes JF: Intramuscular administration of vascular andothelial growth factor induces dose-dependent collateral artery augmentation in a rabbit model of chronic limb ischemia. Circulation 1994, 90:II228-II234.
117. Walder CE, Errett CJ, Ogez J, Heinshon H, Bunting S, Lindquist P, Ferrara N, Thomas GR: Vascular endothelial growth factor (VEGF) improves blood flow and function in a chronic ischemic hind-limb model. J Cardiovasc Pharmacol (in press). This study provides the critical demonstration that VEGF-induced angiogenesis results in improved ability of the ischemic muscle to function and perform work.
118. Bauters C, Asahara T, Zheng LP, Takeshita S, Bunting S, Ferrara N, Symes JF, Isner JM: Physiologic assessment of augmented vascularity induced by VEGF in a rabbit ischemic hindlimb model. Am J Physiol 1894, 267:H1263-H1271.
119. Bauters C, Asahara T, Zheng LP, Takeshita S, Bunting S, Ferrara N, Symes JF, Isner JM: Recovery of disturbed endothelium-dependent flow in collateral perfused rabbit ischemic hindlimb following administration of VEGF. Circulation 1995, 91:2793-2801. This study demonstrates that the endothelium in VEGF-induced collaterals is functional, and displays reactivity to acetylcholine and serotonin.
120. Sellke FW, Kagaya Y, Johnson RG, Shafique T, Schoen FJ, Grossman W, Weintraub RM: Endothelial modulation of porcine coronary microcirculation perfused via immature collaterals. Am J Physiol 1992, 262:H1669-H1695.
121. Graor RA, Gray BH: Interventional treatment of peripheral vascular disease. In Peripheral vascular diseases. Edited by Young JR, Graor RA, Olin JW, Bartholomew JR. St Louis: CV Mosby; 1991:111-133.
122. Essed CD, Brand MVD, Becker AE: Transluminal coronary angioplasty and early restenosis. Br Heart J 1983, 49:393-402.
123. •] indicate that VEGF is able to promote endothelial growth after balloon angioplasy. Remarkably, this effect resulted in a significant inhibition of neointima formation.
124. •].